Literature DB >> 16547060

PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis.

Pauline Yoong1, Raymond Schuch, Daniel Nelson, Vincent A Fischetti.   

Abstract

We have cloned a lytic enzyme, PlyPH, with a specific lytic effect on Bacillus anthracis strains. PlyPH remains active between pH 4 and 10.5, and a single dose rescued a significant percentage of mice infected intraperitoneally with an attenuated B. anthracis strain. We propose PlyPH as a novel therapeutic agent.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16547060      PMCID： PMC1428399          DOI： 10.1128/JB.188.7.2711-2714.2006

Source DB:  PubMed          Journal:  J Bacteriol        ISSN： 0021-9193            Impact factor:   3.490


  33 in total

1.  In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne.

Authors:  C H Choe; S S Bouhaouala; I Brook; T B Elliot; G B Knudson
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 2.  Recognition and management of anthrax--an update.

Authors:  M N Swartz
Journal:  N Engl J Med       Date:  2001-11-06       Impact factor: 91.245

3.  Phage antibacterials make a comeback.

Authors:  V A Fischetti
Journal:  Nat Biotechnol       Date:  2001-08       Impact factor: 54.908

4.  Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.

Authors:  J M Loeffler; D Nelson; V A Fischetti
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

Review 5.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

6.  Fluorescent Amplified Fragment Length Polymorphism Analysis of Norwegian Bacillus cereus and Bacillus thuringiensis Soil Isolates.

Authors:  L O Ticknor; A B Kolstø; K K Hill; P Keim; M T Laker; M Tonks; P J Jackson
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

Review 7.  Biological roles of two new murein hydrolases of Streptococcus pneumoniae representing examples of module shuffling.

Authors:  R López; M P González; E García; J L García; P García
Journal:  Res Microbiol       Date:  2000 Jul-Aug       Impact factor: 3.992

8.  C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates.

Authors:  Martin J Loessner; Karl Kramer; Frank Ebel; Siegfried Scherer
Journal:  Mol Microbiol       Date:  2002-04       Impact factor: 3.501

9.  A bacteriolytic agent that detects and kills Bacillus anthracis.

Authors:  Raymond Schuch; Daniel Nelson; Vincent A Fischetti
Journal:  Nature       Date:  2002-08-22       Impact factor: 49.962

Review 10.  Bacillus anthracis and antibacterial agents.

Authors:  A Bryskier
Journal:  Clin Microbiol Infect       Date:  2002-08       Impact factor: 8.067
View more
  26 in total

1.  Expression of green fluorescent protein fused to magnetosome proteins in microaerophilic magnetotactic bacteria.

Authors:  Claus Lang; Dirk Schüler
Journal:  Appl Environ Microbiol       Date:  2008-06-06       Impact factor: 4.792

Review 2.  Recombinant bacteriophage lysins as antibacterials.

Authors:  Mark Fenton; Paul Ross; Olivia McAuliffe; Jim O'Mahony; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

3.  A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia.

Authors:  Rolf Lood; Assaf Raz; Henrik Molina; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

4.  Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient.

Authors:  Soo Youn Jun; Gi Mo Jung; Seong Jun Yoon; Yun-Jaie Choi; Woo Suk Koh; Kyoung Sik Moon; Sang Hyeon Kang
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

5.  Lytic enzyme discovery through multigenomic sequence analysis in Clostridium perfringens.

Authors:  Jonathan E Schmitz; Maria Cristina Ossiprandi; Kareem R Rumah; Vincent A Fischetti
Journal:  Appl Microbiol Biotechnol       Date:  2010-11-18       Impact factor: 4.813

Review 6.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

7.  Characterization of AmiBA2446, a novel bacteriolytic enzyme active against Bacillus species.

Authors:  Krunal K Mehta; Elena E Paskaleva; Saba Azizi-Ghannad; Daniel J Ley; Martin A Page; Jonathan S Dordick; Ravi S Kane
Journal:  Appl Environ Microbiol       Date:  2013-07-19       Impact factor: 4.792

Review 8.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

9.  Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo.

Authors:  Hang Yang; Yun Zhang; Junping Yu; Yanling Huang; Xian-En Zhang; Hongping Wei
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

10.  Characteristics of a broad lytic spectrum endolysin from phage BtCS33 of Bacillus thuringiensis.

Authors:  Yihui Yuan; Qin Peng; Meiying Gao
Journal:  BMC Microbiol       Date:  2012-12-19       Impact factor: 3.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.